Trends In Immunotherapy And Survival Outcomes In Patients With Stage IV Cancer For Eight Major Cancers In The United States

Samantha Warwar; Lauren Janczewski; Gladys Rodriguez; Jeffrey Wayne; David Bentrem Department of Surgery, Northwestern University Feinberg School of Medicine

BACKGROUND


- Late-stage cancers have poor survival
- Recent advances in immunotherapy (IO) have transformed the management of certain historically hard-to-treat cancers
- It is unclear how IO and survival have evolved in individual advanced cancers

OBJECTIVES

- Report IO use for high-incident stage IV cancers over time
- Evaluate trends in stage IV cancer overall survival (OS) by cancer site

METHODS

- Patients diagnosed with stage IV prostate, breast, melanoma, colorectal, kidney, bladder, lung, or pancreas cancer (2004-2020) were identified from The National Cancer Database
- Time periods were defined as [1] 2004-2010, [2] 2011-2015, [3] 2016-2019
- Kaplan-Meier methods estimated OS
- Absolute differences in 3-year OS and IO rates from periods
- 1 to 3 allowed for comparison among cancer sites



IMMUNOTHERAPY USE

Increased from 1.0% to 24.6%

FROM PERIODS 1 TO 3 IN ALL SITES COMBINED...

OVERALL SURVIVAL

3- and 5-yr OS increased (Figure 1) 3-yr: 13.3% to 26.1% 5-yr: 7.9% to 17.7%

FROM PERIODS 1 TO 3 BY CANCER SITE ...

IMMUNOTHERAPY USE

Melanoma had the highest increase in IO from 9.5% to 58.5% (Figure 2)

Pancreas had the lowest uptake of IO from 0.3% to 1.1%

OVERALL SURVIVAL

Absolute increases in 3-year OS rates ranged from 3.4% in pancreas (1.7% to 5.1%) to 21.4% in melanoma (15.7% to 37.1%)

(Figure 3)




Figure 2. Immunotherapy Use By Tumor Site Per Time Period. Y axis: percentage of patients diagnosed with cancer site of interest in a particular time period who received immunotherapy out of the total number of patients diagnosed during the same year

MEDIAN SURVIVAL

Increased from 6. 6 to 10.8 months

MEDIAN SURVIVAL

Doubled in melanoma from 7.1 to 14.9 months





Figure 3. Trends In 3-year Overall Survival Rates In Patients With Stage IV Cancer By Tumor Site

M Northwestern Medicine[®] Feinberg School of Medicine



CONCLUSION

- The 3- and 5-yr survival of stage IV cancers has improved over time, though there is diverse progress among cancer sites
- IO use for stage IV cancers has increased over time, though less so in pancreas, prostate, and bladder cancer
- Melanoma's notable improvement in survival is likely due to immunotherapy advancements